Cavan M. Redmond
CIK 1420120 · Chief Executive Officer · last filed 2022-07-19
Cavan M. Redmond is a Chief Executive Officer who has filed 27 SEC Form 4 insider transactions across 5 companies since 2008. The most recent filing, for OCX, was dated Jul 19, 2022. Across all open-market trades the lifetime net is +$47.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions. 2 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OCX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MADISON, NJ 07940
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 6,043 | $3.20 | $19.3K | $47.6K | 10 | 2022-07-19 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | — | — | — | $0 | 1 | 2018-07-03 |
| WebMD Health Corp. (WBMD) Delisted | Chief Executive Officer | 45,000 | — | — | $0 | 2 | 2012-06-28 |
| PFE | Group President | 184,840 | $29.56 | $5.46M | $0 | 7 | 2012-06-01 |
| WYETH (WYE) Delisted | Pres., Wyeth Consumer Health. | 66,701 | — | — | $0 | 6 | 2009-04-29 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Exer (M) | +10,000 | $0 | EDGAR |
| 2022-03-16 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +40,000 | $47.6K | EDGAR |
| 2021-06-28 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-15 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +18,416 | $0 | EDGAR |
| 2020-06-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-09-04 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-31 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +52,447 | $0 | EDGAR |
| 2018-07-03 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.